PRAX
Praxis Precision Medicines, Inc. NASDAQ Listed Oct 16, 2020$332.67
Mkt Cap $7.0B
52w Low $35.21
92.7% of range
52w High $356.00
50d MA $318.16
200d MA $206.89
P/E (TTM)
-24.1x
EV/EBITDA
-20.7x
P/B
8.3x
Debt/Equity
0.0x
ROE
-34.5%
P/FCF
-26.6x
RSI (14)
—
ATR (14)
—
Beta
2.97
50d MA
$318.16
200d MA
$206.89
Avg Volume
417.9K
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
99 High Street · Boston, MA 02110 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 338.07 | +3.2% | -1.4% | — | — | — | — | — |
| May 4, 2026 | BMO | — | — | — | 324.20 | -0.5% | +4.1% | -1.3% | +1.4% | -1.4% | — | — |
| Feb 19, 2026 | BMO | -3.13 | -3.50 | -12.0% | 328.93 | -4.2% | +0.8% | +1.1% | +2.1% | +0.1% | +1.4% | — |
| Nov 5, 2025 | BMO | -3.45 | -3.36 | +2.6% | 171.75 | -1.5% | -4.1% | +4.7% | -2.4% | -0.2% | +9.3% | — |
| Aug 4, 2025 | BMO | -3.40 | -3.31 | +2.6% | 54.09 | -3.9% | -5.5% | -6.5% | +1.7% | -2.7% | -2.8% | — |
| May 2, 2025 | BMO | -3.20 | -3.29 | -2.8% | 38.06 | +1.8% | +5.7% | -3.2% | -9.7% | +8.3% | -0.1% | — |
| Feb 28, 2025 | BMO | -2.76 | -2.94 | -6.5% | 65.03 | -38.9% | -40.6% | -13.1% | +7.9% | +4.5% | +0.1% | — |
| Nov 6, 2024 | BMO | -2.01 | -2.75 | -36.8% | 72.73 | -2.4% | -1.2% | +4.8% | +3.4% | +8.9% | -2.2% | — |
| Aug 13, 2024 | BMO | -2.38 | -1.74 | +26.9% | 51.82 | -4.3% | +0.8% | -1.9% | +6.3% | -3.0% | -1.9% | — |
| May 13, 2024 | BMO | -2.01 | -2.84 | -41.3% | 48.78 | -3.4% | -7.4% | +1.6% | -4.1% | +2.8% | +0.4% | — |
| Mar 5, 2024 | BMO | -3.15 | -2.97 | +5.7% | 54.71 | +2.4% | -1.9% | +8.3% | -3.0% | -0.7% | -5.2% | — |
| Nov 7, 2023 | BMO | -5.25 | -2.70 | +48.6% | 14.79 | +8.5% | +6.5% | -4.8% | -1.9% | -0.1% | -11.2% | — |
| Aug 9, 2023 | BMO | -9.90 | -7.35 | +25.8% | 14.49 | -1.7% | +0.4% | +10.3% | +2.8% | +2.7% | -0.9% | — |
| May 11, 2023 | BMO | -11.24 | -10.64 | +5.3% | 16.05 | +1.9% | +0.0% | -2.8% | +3.8% | -2.8% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Needham | Maintains | Buy → Buy | — | $317.00 | $325.95 | +2.8% | +8.4% | -1.1% | -5.7% | +6.9% | +0.0% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $310.11 | $309.41 | -0.2% | -1.1% | +4.4% | +0.0% | -1.3% | +0.3% |
| Apr 6 | BTIG | Maintains | Buy → Buy | — | $310.38 | $318.76 | +2.7% | -0.1% | -1.1% | +4.4% | +0.0% | -1.3% |
| Feb 20 | Baird | Maintains | Outperform → Outperform | — | $331.61 | $332.52 | +0.3% | +1.1% | +2.1% | +0.1% | +1.4% | -2.0% |
| Feb 20 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $331.61 | $332.52 | +0.3% | +1.1% | +2.1% | +0.1% | +1.4% | -2.0% |
| Feb 20 | Wedbush | Maintains | Underperform → Underperform | — | $331.61 | $332.52 | +0.3% | +1.1% | +2.1% | +0.1% | +1.4% | -2.0% |
| Feb 20 | Truist | Maintains | Buy → Buy | — | $331.61 | $332.52 | +0.3% | +1.1% | +2.1% | +0.1% | +1.4% | -2.0% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $319.54 | $325.40 | +1.8% | +0.3% | +0.9% | +3.0% | -4.7% | +3.4% |
| Feb 4 | Needham | Maintains | Buy → Buy | — | $310.52 | $311.75 | +0.4% | -2.3% | +0.8% | +4.6% | -0.0% | +0.3% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $314.28 | $315.00 | +0.2% | -0.1% | -1.6% | +0.5% | -2.3% | +0.8% |
| Jan 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $314.75 | $323.00 | +2.6% | -1.5% | +1.4% | -0.1% | -1.6% | +0.5% |
| Jan 12 | Wedbush | Maintains | Underperform → Underperform | — | $288.45 | $283.00 | -1.9% | -4.4% | +1.8% | +6.3% | -0.2% | +6.6% |
| Dec 29 | BTIG | Maintains | Buy → Buy | — | $268.95 | $317.72 | +18.1% | +13.2% | -2.5% | -0.8% | -2.8% | -3.3% |
| Dec 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $268.80 | $272.46 | +1.4% | +2.8% | -0.7% | -3.2% | +1.3% | +1.4% |
| Dec 9 | Jefferies | Maintains | Buy → Buy | — | $270.98 | $271.00 | +0.0% | -4.7% | +1.3% | +2.2% | +0.6% | +2.8% |
| Dec 9 | Guggenheim | Maintains | Buy → Buy | — | $270.98 | $271.00 | +0.0% | -4.7% | +1.3% | +2.2% | +0.6% | +2.8% |
| Dec 8 | BTIG | Maintains | Buy → Buy | — | $247.99 | $256.92 | +3.6% | +9.3% | -4.7% | +1.3% | +2.2% | +0.6% |
| Dec 8 | Truist | Maintains | Buy → Buy | — | $247.99 | $256.92 | +3.6% | +9.3% | -4.7% | +1.3% | +2.2% | +0.6% |
| Dec 8 | TD Cowen | Maintains | Buy → Buy | — | $247.99 | $256.92 | +3.6% | +9.3% | -4.7% | +1.3% | +2.2% | +0.6% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $247.99 | $256.92 | +3.6% | +9.3% | -4.7% | +1.3% | +2.2% | +0.6% |
| Dec 8 | Needham | Maintains | Buy → Buy | — | $247.99 | $256.92 | +3.6% | +9.3% | -4.7% | +1.3% | +2.2% | +0.6% |
| Dec 5 | Wedbush | Maintains | Underperform → Underperform | — | $189.97 | $241.00 | +26.9% | +30.5% | +9.3% | -4.7% | +1.3% | +2.2% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $189.97 | $241.00 | +26.9% | +30.5% | +9.3% | -4.7% | +1.3% | +2.2% |
| Dec 5 | Needham | Maintains | Buy → Buy | — | $189.97 | $241.00 | +26.9% | +30.5% | +9.3% | -4.7% | +1.3% | +2.2% |
| Dec 1 | Needham | Maintains | Buy → Buy | — | $196.46 | $193.44 | -1.5% | -6.1% | -2.9% | +3.9% | +2.1% | +30.5% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $190.86 | $191.59 | +0.4% | -3.5% | +2.3% | +4.2% | -6.1% | -2.9% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $183.61 | $184.15 | +0.3% | -3.0% | +4.7% | +6.0% | -6.8% | +2.8% |
| Nov 6 | Wedbush | Maintains | Underperform → Underperform | — | $164.64 | $164.01 | -0.4% | +4.7% | -2.4% | -0.2% | +9.3% | +0.0% |
| Oct 20 | Wedbush | Maintains | Underperform → Underperform | — | $189.99 | $190.00 | +0.0% | -7.9% | +8.5% | -2.9% | -3.5% | -2.3% |
| Oct 17 | Deutsche Bank | Maintains | Buy → Buy | — | $162.71 | $178.90 | +10.0% | +16.8% | -7.9% | +8.5% | -2.9% | -3.5% |
| Oct 17 | Guggenheim | Maintains | Buy → Buy | — | $162.71 | $178.90 | +10.0% | +16.8% | -7.9% | +8.5% | -2.9% | -3.5% |
| Oct 17 | Chardan Capital | Maintains | Buy → Buy | — | $162.71 | $178.90 | +10.0% | +16.8% | -7.9% | +8.5% | -2.9% | -3.5% |
| Oct 17 | Truist | Maintains | Buy → Buy | — | $162.71 | $178.90 | +10.0% | +16.8% | -7.9% | +8.5% | -2.9% | -3.5% |
| Oct 16 | Jefferies | Maintains | Buy → Buy | — | $57.35 | $158.29 | +176.0% | +183.7% | +16.8% | -7.9% | +8.5% | -2.9% |
| Oct 16 | Needham | Maintains | Buy → Buy | — | $57.35 | $158.29 | +176.0% | +183.7% | +16.8% | -7.9% | +8.5% | -2.9% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $57.35 | $158.29 | +176.0% | +183.7% | +16.8% | -7.9% | +8.5% | -2.9% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.09 | $53.05 | +3.8% | -6.5% | +1.7% | -2.7% | -2.8% | -2.2% |
| Jul 29 | Chardan Capital | Maintains | Buy → Buy | — | $55.65 | $57.72 | +3.7% | +0.6% | +1.1% | -4.2% | -0.2% | -5.5% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.94 | $55.53 | +1.1% | -2.0% | +2.4% | +0.5% | +3.0% | +1.6% |
| Jul 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.68 | $47.37 | +1.5% | +0.2% | +7.4% | +0.2% | +0.5% | +6.1% |
| Jun 12 | Needham | Maintains | Buy → Buy | — | $44.60 | $44.01 | -1.3% | +1.0% | -1.6% | -1.1% | -0.8% | -1.1% |
| May 5 | Needham | Maintains | Buy → Buy | — | $40.24 | $40.89 | +1.6% | -3.2% | -9.7% | +8.3% | -0.1% | +0.8% |
| May 5 | Wedbush | Maintains | Underperform → Underperform | — | $40.24 | $40.89 | +1.6% | -3.2% | -9.7% | +8.3% | -0.1% | +0.8% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.64 | $37.44 | -0.5% | +1.1% | +5.7% | -3.2% | -9.7% | +8.3% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $31.53 | $33.99 | +7.8% | -9.3% | +7.9% | -7.7% | +4.5% | +0.0% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $38.60 | $38.61 | +0.0% | -13.1% | +7.9% | +4.5% | +0.1% | +1.7% |
| Mar 3 | Truist | Maintains | Buy → Buy | — | $38.60 | $38.61 | +0.0% | -13.1% | +7.9% | +4.5% | +0.1% | +1.7% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.60 | $38.61 | +0.0% | -13.1% | +7.9% | +4.5% | +0.1% | +1.7% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $38.60 | $38.61 | +0.0% | -13.1% | +7.9% | +4.5% | +0.1% | +1.7% |
| Feb 10 | Needham | Maintains | Buy → Buy | — | $86.88 | $88.75 | +2.2% | -2.3% | -0.7% | +1.4% | +1.5% | +4.7% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This 8-K filing lacks substantive disclosure details, making it impossible to assess material impact; investors should review the actual filing or company announcements for clarity on what event triggered this report.
Apr 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA priority review of relutrigine for rare genetic epilepsies suggests accelerated approval timeline, potentially creating near-term catalyst that could drive PRAX stock higher if development progresses successfully.
Apr 6
8-K
Praxis Precision Medicines, Inc. -- 8-K Filing
Praxis Precision Medicines advanced its pipeline with two FDA drug applications for ulixacaltamide and relutrigine, positioning the company for potential near-term approvals and 2026 commercialization launches in neurology markets.
Feb 19
8-K · 5.02
!!! Very High
Praxis Precision Medicines, Inc. -- 8-K 5.02: Executive Change
Praxis Precision Medicines adds Jeffrey B. Kindler to its board of directors, effective January 8, 2026, potentially bringing additional oversight and strategic guidance to the clinical-stage pharmaceutical company.
Feb 10
Data updated apr 26, 2026 8:34pm
· Source: massive.com